CooperCompanies Announces Second Quarter 2025 Results

Core Insights - CooperCompanies reported solid financial results for the fiscal second quarter ended April 30, 2025, with a total revenue increase of 6% year-over-year to $1,002.3 million, driven by growth in both CooperVision and CooperSurgical segments [5][6][42] - The company emphasized its focus on market share expansion, product launches, and capacity expansion projects moving forward [2] Financial Performance - CooperVision (CVI) revenue increased by 5% year-over-year to $669.6 million, with organic growth of 7% [5][42] - CooperSurgical (CSI) revenue rose by 8% year-over-year to $332.7 million, with organic growth of 7% [5][42] - Gross margin improved to 68% from 67% in the previous year, attributed to efficiency gains [6][18] - Non-GAAP diluted earnings per share (EPS) increased by 14% to $0.96, while GAAP diluted EPS remained consistent at $0.44 [5][40] Revenue Breakdown - Total revenue of $1,002.3 million consisted of CooperVision's $669.6 million and CooperSurgical's $332.7 million [5][42] - Revenue by geography showed the Americas at $282.4 million (up 7%), EMEA at $248.6 million (up 5%), and Asia Pacific at $138.6 million (up 3%) [3][42] Operational Highlights - The company generated free cash flow of $18.1 million after capital expenditures of $78.1 million [6][8] - Interest expense decreased to $24.2 million from $28.9 million due to lower interest rates and reduced average debt [6][40] Share Repurchase Program - During the second quarter, CooperCompanies repurchased $40.6 million of common stock, approximately 537.2 thousand shares, at an average price of $75.60 [8] Fiscal Year 2025 Guidance - The company updated its fiscal year 2025 financial guidance, projecting total revenue between $4,107 million and $4,146 million, with organic growth of 5% to 6% [14]